Kura Oncology, Inc. (NASDAQ:KURA) Shares Sold by Affinity Asset Advisors LLC

Affinity Asset Advisors LLC reduced its stake in shares of Kura Oncology, Inc. (NASDAQ:KURA) by 11.0% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 650,000 shares of the company’s stock after selling 80,492 shares during the period. Kura Oncology accounts for about 1.5% of Affinity Asset Advisors LLC’s holdings, making the stock its 17th biggest position. Affinity Asset Advisors LLC owned about 0.85% of Kura Oncology worth $13,384,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently bought and sold shares of KURA. ProShare Advisors LLC boosted its stake in Kura Oncology by 9.7% in the 1st quarter. ProShare Advisors LLC now owns 18,014 shares of the company’s stock worth $384,000 after buying an additional 1,588 shares during the last quarter. Aaron Wealth Advisors LLC grew its stake in shares of Kura Oncology by 2.4% during the second quarter. Aaron Wealth Advisors LLC now owns 70,148 shares of the company’s stock valued at $1,444,000 after acquiring an additional 1,673 shares in the last quarter. Hsbc Holdings PLC increased its position in shares of Kura Oncology by 13.4% during the second quarter. Hsbc Holdings PLC now owns 18,300 shares of the company’s stock worth $374,000 after acquiring an additional 2,167 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of Kura Oncology by 17.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 20,148 shares of the company’s stock worth $430,000 after acquiring an additional 2,940 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Kura Oncology by 34.7% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 18,060 shares of the company’s stock worth $372,000 after acquiring an additional 4,654 shares in the last quarter.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on KURA. StockNews.com downgraded shares of Kura Oncology from a “hold” rating to a “sell” rating in a research report on Thursday, August 22nd. JMP Securities restated a “market outperform” rating and set a $32.00 price objective on shares of Kura Oncology in a research note on Monday, August 12th. HC Wainwright reiterated a “buy” rating and issued a $32.00 target price on shares of Kura Oncology in a research report on Monday, August 12th. Wedbush reaffirmed an “outperform” rating and issued a $37.00 price objective on shares of Kura Oncology in a report on Friday, August 9th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a research report on Monday, September 9th. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $30.60.

Kura Oncology Price Performance

Shares of KURA opened at $19.82 on Wednesday. Kura Oncology, Inc. has a 12 month low of $7.41 and a 12 month high of $24.17. The company has a debt-to-equity ratio of 0.02, a quick ratio of 14.94 and a current ratio of 14.94. The stock has a fifty day moving average price of $20.13 and a 200 day moving average price of $20.57.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.59) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.04. The business’s revenue for the quarter was up .0% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.53) earnings per share. As a group, sell-side analysts anticipate that Kura Oncology, Inc. will post -2.45 EPS for the current fiscal year.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.